OLD Category: immuno-oncology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

• Blank C.U. et. al.,

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

• Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA

Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy

• Medler T.R. et. al.,

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

• Ribas A. et. al.,

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

• Hagihara K. et al.,

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma

• Kim M. et. al.,

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

• Leivonen S.K. et. al.,

Computational measurement of tumor immune microenvironment in gastric adenocarcinomas

• Chang Y.H. et. al.,

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer

• Foulds G.A. et. al.,

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS

• Sugio T. et. al.,

hsa-miR-24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c-Myc/epithelial-mesenchymal transition axis

• Su B. et. al.,